CUV
Clinuvel Pharmaceuticals
Clinuvel Pharmaceuticals Ltd. is a pioneering Australian company specializing in the development of innovative treatments for UV and light-related skin disorders. Their flagship product, SCENESSE®, is the first systemic photoprotective drug approved for preventing phototoxicity in patients with erythropoietic protoporphyria. The company leverages its expertise in photomedicine and melanocortin pep...
Shorted
About
website
industry
address
Key Metrics
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Short Position Trends
Track bearish sentiment and short interest over time
Historical Price Data
View stock price movements, volume, and trading patterns
Industry & Focus
Company Overview
AI-generated company summary
Clinuvel Pharmaceuticals Ltd. is a pioneering Australian company specializing in the development of innovative treatments for UV and light-related skin disorders. Their flagship product, SCENESSE®, is the first systemic photoprotective drug approved for preventing phototoxicity in patients with erythropoietic protoporphyria. The company leverages its expertise in photomedicine and melanocortin peptides to address unmet medical needs globally.
Company History
Founded in 2001, Clinuvel Pharmaceuticals has evolved into a global leader in photomedicine. The company achieved a significant milestone with the approval of SCENESSE® in Europe, the USA, Israel, and Australia. Over the years, Clinuvel has expanded its operations to include offices in Europe, Singapore, and the USA, focusing on developing novel treatments for genetic and metabolic disorders.
Competitive Advantages
Clinuvel's competitive advantages include its pioneering role in photomedicine, the unique approval of SCENESSE® as the first systemic photoprotective drug, and its strong focus on addressing unmet medical needs in niche markets.
Risk Factors
- •Regulatory approval challenges
- •Market competition from larger pharmaceutical companies
- •Dependence on the success of SCENESSE®
Recent Developments
Last 6 months
In the past six months, Clinuvel has focused on expanding its market presence and enhancing its product offerings, including updates on SCENESSE® and other pipeline products.
Key People
Leadership team at Clinuvel Pharmaceuticals
Philippe Wolgen
CEO
Philippe Wolgen has been leading Clinuvel Pharmaceuticals as CEO, driving the company's strategic vision and global expansion.
Darren Keamy
CFO
Darren Keamy serves as the CFO of Clinuvel Pharmaceuticals, overseeing the financial operations and contributing to the company's financial strategy.
Financial Reports
21 reports available
Showing 10 of 21 reports